UK Terminates COVID-19 Vaccine Deal, But Valneva Can Bounce Back
Two Other Vaccines Show Promise
The UK’s decision has hit Valneva’s share price hard, but its vaccine candidates in Chikungunya and Lyme’s disease should help the firm bounce back.
You may also be interested in...
New developments on the COVID-19 front also include the European Medicines Agency starting a rolling review of Valneva’s investigational COVID-19 vaccine, and the UK government signing contracts with Pfizer/BioNTech and Moderna to buy more doses of their vaccines.
The European Commission has approved a purchase deal for Valneva’s COVID-19 vaccine candidate just months after the UK scrapped its own deal with the firm.
Immunogenicity data from Valneva’s COV-COMPARE study are encouraging, but the inactivated vaccine will need proper efficacy data to gain a toehold in a crowded market.